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Summary
Introduction:  Management  of  osteoarticular  infections  combines  surgical  treatment  with  antibi-
otic therapy.  For  some  teams  the  immediate  postoperative  regimen  requires  at  least  partly
wide-spectrum  probabilistic  treatment  while  waiting  for  the  microbiological  results.  This  pro-
tocol exposes  the  patient  to  the  selection  of  resistant  bacteria  and  the  hospital  unit  to  a
modiﬁcation  of  its  bacterial  ecology.  The  objective  of  this  study  was  to  retrospectively  describe
the microbial  epidemiology  of  the  Traumatology  and  Orthopaedics  Department  of  the  Lille
University Hospital  over  10  years  (2002—2011).
Materials  and  methods:  The  bacterial  species  isolated  in  culture  of  osteoarticular  samples  were
listed, after  removing  any  duplicates.  The  antibiotics  retained  for  follow-up  were  those  used  in
treatment  of  these  infections  as  well  as  those  recognized  as  markers  of  resistance.  For  Gram-
positive species,  the  antibiotics  considered  were  methicillin,  rifampicin,  ﬂuoroquinolones,
glycopeptides,  and  linezolid;  for  the  Gram-negative  species,  cefotaxime,  cefepime,  imipenem,
and ﬂuoroquinolones  were  considered.
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Results:  Of  the  5006  strains  isolated  between  2002  and  2011,  Gram-positive  cocci  accounted
for more  than  71%;  Staphylococcus  aureus  27%,  and  coagulase-negative  staphylococci  (CoNS)
54%. Contrary  to  S.  aureus,  resistance  to  methicillin,  ﬂuoroquinolones,  and  teicoplanin  signif-
icantly  increased  in  CoNS,  reaching  44%,  34%,  and  22%,  respectively,  of  the  strains  in  2011.
The proportion  of  streptococcal  and  enterococcal  infections  remained  stable,  a  mean  7.4%
and 5.3%,  respectively,  per  year.  Enterobacteria  (12.5%  of  the  isolates)  were  producers  of
extended-spectrum  beta-lactamase  in  7.8%  of  the  cases.  Pseudomonas  aeruginosa  was  involved
in 3.6%  of  the  infections,  and  12%  of  the  strains  remained  resistant  to  ceftazidime.  Propionibac-
terium acnes  accounted  for  5.8%  of  the  bacteria  isolated  and  showed  few  antibiotic  resistance
problems.
Discussion:  Stability  in  the  distribution  and  the  susceptibility  of  different  bacterial  species  was
noted over  this  10-year  period.  Although  the  evolution  of  S.  aureus  resistance  was  favourable,
the resistance  of  CoNS  specially  to  methicillin  and  glycopeptides  increased.
Level of  evidence:  Level  IV.  Retrospective  cohort  study.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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nfection  is  one  of  the  most  dreaded  complications  in  trau-
atology  and  orthopaedic  surgery,  requiring  management
y  a  multidisciplinary  team.  Wide-spectrum  probabilistic
ntibiotic  therapy  is  often  necessary  during  revision  surgery
1].  This  protocol  exposes  the  patient  to  the  selection  of
esistant  bacteria  and  is  not  without  consequences  on  the
nit’s  bacterial  ecology.  One  of  the  major  issues  for  referent
enters  for  complex  osteoarticular  infection  (CRIOAC),  cre-
ted  in  2008,  is  the  institution  of  a  reasoned  prescription  of
ntibiotics  so  as  to  protect  the  most  active  drugs  in  this  type
f  infection  via  a  multidisciplinary  approach.  The  objec-
ive  of  this  study  was  to  evaluate  the  evolution  of  bacterial
pidemiology  over  the  past  10  years  in  the  Traumatology
nd  Orthopaedics  units  of  the  Lille  University  Hospital,  the
RIOAC  of  Northern  France.  We  studied  all  the  bacterial
pecies  involved  in  osteoarticular  infections  (OAIs)  as  well
s  the  evolution  of  their  resistance  to  antibiotics  so  as  to
dapt  the  referent  center’s  therapeutic  protocols  to  this
pidemiology.
aterial and methods
ver  a  10-year  period  (2002—2011),  using  the  laboratory’s
omputerized  systems  (Molis  V3  and  V4,  Vision4health,
aris)  we  retrospectively  collected  all  the  bacterial  species
solated  from  osteoarticular  samples  taken  in  the  Trauma-
ology  and  Orthopaedics  Units  of  Roger  Salengro  Hospital
f  Lille  University  Hospital.  Any  duplicates  were  removed.
hese  samples  were  taken  pre-  or  intraoperatively:  they
ere  bone,  joint,  and  soft  tissue  (cutaneous,  musculotendi-
ous)  or  material  samples.  The  strains  came  from  standard
edium  cultures  or  enriched  broth  cultures  according  to
he  laboratory’s  protocol  [2].  The  species  were  identi-
ed  by  automated  techniques:  from  2001  to  2009  API®
trips  (Biomérieux,  Marcy  l’Étoile,  France)  and  VITEK2®ards  (Biomérieux,  Marcy  l’Étoile,  France)  were  used;  since
009  MALDI-TOF  mass  spectrometry  (Microﬂex  Biotyper  2.0,
ruker  Daltonics,  GmbH,  Bremen,  Germany)  has  become
he  exclusive  identiﬁcation  technique.  The  antimicrobial
S
S
1usceptibility  tests  were  also  performed  on  the  VITEK2®
utomate  (Biomérieux,  Marcy  l’Étoile,  France)  for  the
taphylococci,  enterococci,  enterobacteria,  and  the  main
on-fermenting  Gram-negative  bacilli  (e.g.,  Pseudomonas
eruginosa). The  diffusion  agar  technique  was  used  for  the
ost  fastidious  species  such  as  streptococci  and  anaerobic
pecies.  The  procedure  and  interpretation  of  the  suscepti-
ility  tests  were  in  accordance  with  the  recommendations
f  the  CA-SFM  (Comité  de  l’Antibiogramme  de  la  Société
ranc¸aise  de  Microbiologie).
According  to  the  probabilistic  unit  protocol,  the  non-
usceptibility  (intermediate  or  resistant  character)  of  the
trains  were  considered:  amoxicillin,  glycopeptides  and  line-
olid,  and  methicillin  (a  resistance  marker  for  staphylococci)
or  Gram-positive  bacteria,  and  third-  and  fourth-generation
ephalosporins  —  cefotaxime  and  cefepime,  respectively
 as  well  as  imipenem  for  Gram-negative  species.  More-
ver,  resistance  involving  drugs  used  after  documentation
f  the  infection  was  also  taken  into  account:  for  the  Gram-
ositive  species,  resistance  to  rifampicin,  ﬂuoroquinolones,
lycopeptides,  and  linezolid;  for  the  Enterobacteria,  resis-
ance  to  cefotaxime,  imipenem,  and  ﬂuoroquinolones;
nally,  for  the  non-fermenting  Gram-negative  bacilli  (e.g.,
.  aeruginosa), resistance  to  ceftazidime,  imipenem,  and
uoroquinolones  were  considered.
The  statistical  analyses  were  based  on  a  comparison  of
he  means  using  the  Chi2 test.  The  signiﬁcance  threshold
as  set  at  p  <  0.01.
esults
etween  2002  and  2011,  5006  bacterial  strains  were  iso-
ated  from  osteoarticular  samples  (M  =  501  ±  39  strains  per
ear)  (Table  1). The  distribution  of  the  different  species
solated  was  stable  over  the  10  years,  except  for  a  signiﬁ-
ant  (p  =  0.001)  increase  in  the  number  of  Propionibacterium
cnes  strains  isolated  (eight  in  2002  versus  32  in  2011).taphylococcus
taphylococcus  aureus  (n  =  950)  was  identiﬁed  in  a  mean
9.1  ±  2.4%  of  all  the  osteoarticular  samples  taken  between
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Table  1  Distribution  of  bacterial  species  isolated  between  2002  and  2011  in  osteoarticular  samples  examined  by  Traumatology  and  Orthopaedics  Units  of  the  Lille  University
Hospital.
2002  2003  2004  2005  2006  2007  2008  2009  2010  2011  Mean  (±SD) Mean  %  (±SD)
Gram-positive  cocci 446  326  345  342  342  348  331  331  388  339  354  (±37) 70.7  (±4.2)
Staphylococcus aureus 122  81  82  73  83  94  90  114  114  97  95  (±17) 19.1  (±2.4)
CoNS 247  184  187  208  202  195  175  151  204  173  193  (±26) 38.4  (±4.3)
Enterococcus spp. 36  27  23  21  21  26  23  33  24  32  27  (±5) 5.3  (±0.9)
Streptococcus spp. 41  33  50  40  34  32  38  32  46  37  38  (±6) 7.7  (±1.3)
Other GPCs 0  1  3  0  2  1  5  1  0  0  1  (±2) 0.3  (±0.3)
GNB, Enterobacteria 71  50  47  58  48  65  62  73  63  77  61  (±11)  12.3  (±1.7)
Proteus spp. 20  14  19  22  12  21  14  22  15  21  18  (±4)  3.6  (±0.7)
Enterobacter spp. 31  12  13  15  19  19  16  17  12  15  17  (±  6)  3.4  (±0.9)
E. coli  8  15  6  12  6  18  18  17  19  18  14  (±5)  2.7  (±1.0)
Other GNBs  12  9  9  9  11  7  14  17  17  23  13  (±5)  2.5  (±0.9)
Nonfermenting GNB  21  29  33  27  28  29  22  18  23  22  25  (±4)  5.1  (±1.2)
Pseudomonas aeruginosa  18  24  28  21  20  20  7  14  14  17  18  (±6)  3.6  (±1.2)
Anaerobic bacteria 11  23  26  39  53  60  39  46  47  55  40  (±16)  8.0  (±2.9)
Propionibacterium  acnes 8  18  21  32  38  42  30  33  37  32  29  (±10)  5.8  (±2.0)
Gram-positive bacilli 13  6  14  14  20  18  22  24  25  29  19  (±7)  3.7  (±1.3)
Other bacteria/yeasts  0  1  1  0  1  4  4  1  6  0  2  (±2)  1.8  (±2.1)
Total (n  =  5006)  562  435  466  480  492  524  480  493  552  522  501  (±39)
CoNS: coagulase-negative staphylococcus; GPC: Gram-positive cocci; GNB: Gram-negative bacilli.
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Table  2  Gram-positive  cocci:  evolution  of  bacterial  resistance  (intermediate  or  resistant  strains)  to  main  antibiotics  used  in
OAI treatment.
2002  2008  2009  2010  2011  Mean  %  (±SD)
Staphylococcus  aureus
Methicillin  27.9  21.1  21.1  23.7  20.6  22.9  (±3.1)
Levoﬂoxacin  27  22.2  23  31.8  17.7  24.3  (±3.1)
Rifampicin 13.1  6.6  5.3  2.6  1  5.7  (±3.1)
Vancomycin  0  0  0  0  0  0.0  (±0.0)
Teicoplanin  0  0  0  0  0  0.0  (±0.0)
Linezolid NT  0  0  0  0  0.0  (±0.0)
CoNS
Methicillin 30.4  44.3 54.4 49.8 43.9 44.6  (±9.0)
Levoﬂoxacin  20.3  32.5  41.2  24.5  34.1  30.5  (±8.2)
Rifampicin 13  18.3  18.5  20.2  18.5  17.7  (±2.7)
Vancomycin  0.4  0  0  0  2.3  0.5  (±1.0)
Teicoplanin 3.7  14.9  21.3  7.4  22  13.9  (±8.2)
Linezolid NT  1.2  2  1  3.5  1.9  (±1.1)
Enterococcus  spp.
Amoxicillin  22.3  8.6  15.6  12.5  3.1  12.4  (±7.2)
High-concentration  gentamicin  13.9  17.4  12.5  25  9.4  15.6  (±6.0)
Levoﬂoxacin  NT  31.8  32.2  29.2  31.3  31.1  (±1.3)
Rifampicin NT  5  16.6  17.4  6.5  11.4  (±6.5)
Vancomycin  2.8  0  0  4.2  6.2  2.6  (±2.7)
Teicoplanin  0  0  0  0  0  0.0  (±0.0)
Linezolid NT  0  0  0  0  0.0  (±0.0)
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5CoNS: coagulase-negative staphylococcus; NT: not tested.
002  and  2011  (5  ±  17  strains  per  year).  In  2002,  of  the  122
trains  of  S.  aureus  isolated,  27.9%  were  resistant  to  methi-
illin  and  27%  to  ﬂuoroquinolones.  In  2011,  among  the  97
trains  of  S.  aureus  isolated,  20.6%  were  resistant  to  methi-
illin  and  17.7%  to  ﬂuoroquinolones  (non-signiﬁcant).
Resistance  to  rifampicin  decreased  signiﬁcantly
p  = 0.006):  13.1%  of  the  strains  in  2002  versus  1%  in
011.  Finally,  none  of  the  S.  aureus  strains  was  resistant  to
lycopeptides  or  linezolid  over  the  10-year  period.
Coagulase-negative  staphylococci  (CoNS)  (n  =  1926)  were
solated  out  of  all  the  samples  in  38.4  ±  4.3%,  with  a  mean
93  ±  26  strains  per  year.  Contrary  to  S.  aureus, a  signiﬁcant
ncrease  was  observed  in  the  methicillin-resistant  strains,
hich  accounted  for  30.4%  of  the  isolates  in  2002  and  43%
n  2011  (p  =  0.004).  Likewise,  resistance  to  ﬂuoroquinolones
ncreased  from  20%  in  2002  to  34%  in  2011.  Intermediate
r  resistant  strains  to  teicoplanin  increased  from  3.7%  in
002  to  22%  in  2011  (p  <  0.01).  We  also  noted  the  appearance
f  strains  resistant  to  vancomycin  as  well  as  linezolid:  2.3%
nd  3.5%,  respectively,  of  the  strains  in  2011.  Resistance  to
ifampicin  remained  stable  (mean,  17.7%  of  the  strains)  over
he  10  years  (Table  2).
he  Streptococcus  and  Enterococcus  genera
he  streptococci  isolated  every  year  accounted  for
.7  ±  1.3%  of  the  bacteria.  These  species  were  generally
ultisusceptible.
The  enterococci  accounted  for  5.3  ±  0.9%  of  the  strains
uring  the  10  years  studied,  without  major  modiﬁcations
i
P
ieing  noted  in  their  susceptibility.  These  species  were
aturally  resistant  to  third-generation  cephalosporins,  ﬁrst-
eneration  ﬂuoroquinolones,  as  well  as  cotrimoxazole.
ixteen  percent  of  enterococcal  strains  showed  a high-level
esistance  to  gentamicin,  so  in  therapeutic  practice,  there
as  no  synergy  of  this  aminoglycoside  with  ampicillin  or  van-
omycin.  Resistance  to  levoﬂoxacin  was  found  in  31.1  ±  1.3%
f  the  strains.  However,  glycopeptides  and  linezolid  were
ffective  in  100%  of  the  cases  (Table  2).
ram-negative  bacilli
f  the  5006  strains,  866  Gram-negative  bacilli  (GNBs)  were
solated:  71%  corresponding  to  enterobacteria  and  29%  to
on-fermenting  Gram-negative  bacilli  (essentially  of  the
seudomonas  genus).
Among  the  enterobacteria,  the  species  the  most  fre-
uently  isolated  were  Escherichia  coli, Proteus  spp.,
nterobacter  spp.,  and  Klebsiella  spp.  Cefotaxime  remained
ffective  in  89%  of  the  cases  on  average  for  the  2002—2011
eriod  (87%  in  2011).  We  noted  a  non-signiﬁcant  increase
n  the  number  of  strains  of  enterobacteria  resistant  to
iproﬂoxacin  (5.6%  in  2002,  13%  in  2011).  Finally,  the  produc-
ion  of  extended-spectrum  beta-lactamase  (ESBL)  was  only
bserved  in  rare  cases  with  stability  during  the  study  period:
.5%  in  2002,  6%  in  2011  (p  =  1).  Moreover,  for  the  ﬁrst  time
n  2011,  strains  resistant  to  imipenem  were  isolated.
Among  the  non-fermenting  Gram-negative  bacilli,
.  aeruginosa  was  the  most  frequently  found  species:  it  was
nvolved  in  3.6  ±  1.2%  of  the  OAIs  every  year.  In  the  last
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Table  3  Gram-negative  bacilli:  evolution  of  bacterial  resistance  (intermediate  or  resistant  strains)  to  main  antibiotics  used  in
OAI treatment.
2002  2008  2009  2010  2011  Mean  %  (±SD)
Enterobacteria
Amoxicillin  77.4  75.8  76.7  63.5  75.3  73.7  (±5.8)
Amoxicillin —  clavulanic  acid  69  58.2  54.8  41.3  57.2  56.1  (±9.9)
Cefotaxime 15.5  8  9.6  11.1  13  11.4  (±2.9)
Cefepime 7  6.5  5.6  1.6  7.8  5.7  (±2.4)
Imipenem 0  0  0  0  1.6  0.3  (±0.7)
Nalidixic acid 17  17.7  15.1  19  18.2  17.4  (±1.5)
Ciproﬂoxacin  5.6 14.5 12.4 11.1 13  11.3  (±3.4)
Pseudomonas  aeruginosa
Ticarcillin  61.1  85.7  85.7  81.2  82.4  79.2  (±10.3)
Piperacillin-Tazobactam  16.7  0  14.3  18.8  41.2  18.2  (±14.8)
Ceftazidime  16.7  0  7.1  18.8  17.6  12.0  (±8.2)
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decade,  we  noted  an  increase  in  the  resistance  to  ticarcillin
and  to  piperacillin—tazobactam  combination,  from  61.1%
to  82.4%  and  from  16.7%  to  41.2%,  respectively.  Resistance
to  ceftazidime  involved  12  ±  8.2%  of  the  strains  on  average.
At  the  same  time,  resistance  of  strains  to  ciproﬂoxacin
decreased  from  33.6%  in  2002  to  17.6%  in  2011.  These
variations  were  non-signiﬁcant  because  of  the  low  annual
number  of  strains  (18  ±  6)  (Table  3).
Anaerobic  bacteria
Anaerobic  bacteria  were  involved  in  8  ±  2.9%  of  the  OAIs
(Table  1).  Seventy-ﬁve  percent  of  these  anaerobic  bacteria
were  represented  by  P.  acnes, most  particularly  in  pros-
thetic  infections  of  the  upper  limb.  This  Gram-positive
bacilli  naturally  resistant  to  metronidazole  proved  to  be
particularly  susceptible  to  beta-lactams,  rifampicin,  and
ﬂuoroquinolones.  Other  anaerobic  bacterial  species  were
occasionally  found  (Clostridium  spp.),  most  often  envi-
ronmental  bacteria  infecting  wounds  and  open  fractures
treated  in  traumatology.
Discussion
Managing  OAIs  is  based  on  the  efﬁcacy  of  the  perioperative
antimicrobial  therapy  administered  for  a  curative  intent  or
for  a  preventive  intent  in  case  of  implanted  material.  The
choice  of  drug  is  oriented  both  by  rules  of  good  practice  [1]
and  institution  of  protocols  depending  of  local  microbiologi-
cal  data.  This  study  describes  the  evolution  over  10  years  of
the  bacterial  epidemiology  within  a  CRIOAC.  It  is  based  on
the  analysis  of  antimicrobial  susceptibility  tests  of  the  5006
strains  isolated  from  osteoarticular  samples,  both  with  and
without  presence  of  material,  unlike  many  cohorts  reported
in  the  literature  investigating  prosthetic  infections  [3—10].
The  present  study  shows  stability  in  the  distribution
of  the  different  bacterial  species  over  the  10  years.  The
Staphylococcus  genus  remains  the  most  frequent,  with  more
than  58%  of  the  isolates,  a  rate  comparable  with  other  series
[3—6].  The  decrease  observed  in  the  number  of  S.  aureus
i
a
f
f14.2  12.5  17.6  18.4  (±8.6)
esistant  to  methicillin  between  2002  and  2011  is  similar  to
uropean  epidemiology  [11].  At  the  same  time,  an  increased
usceptibility  of  the  S.  aureus  strains  to  rifampicin  and  ﬂu-
roquinolones  was  observed,  probably  related  to  regulated
rescription  of  these  drugs  within  the  referent  center.  How-
ver,  S.  aureus  only  accounted  for  33%  of  the  Staphylococcus
trains  isolated  every  year.  The  CoNS  are  the  most  fre-
uently  isolated,  as  in  other  series  [3,7—9,12].  These  strains
re  resistant  to  methicillin  in  45%  of  cases  on  average,  a
ate  comparable  to  that  observed  by  Tsuyakama  et  al.  [3]
48%)  but  much  lower  than  the  rate  reported  by  Hellmark
t  al.  [12]  (85%).  Over  the  10-year  period  studied,  a  sig-
iﬁcant  increase  in  the  resistance  of  CoNS  to  glycopeptides
as  observed,  notably  to  teicoplanin,  which  involved  22%
f  the  strains  in  2011.  This  rate  is  more  than  four  times
igher  than  that  reported  by  Cremniter  et  al.  in  2010  [13]
4.8%)  concerning  a  series  of  315  CoNS  strains  isolated  in  a
ontext  of  OAI.  Given  the  high  minimal  inhibitory  concen-
rations  (>  8  mg/l)  of  the  strains  concerned,  this  increase
n  resistance  to  glycopeptides  was  not  caused  by  modiﬁca-
ions  in  the  CA-SFM’s  breakpoints  in  the  interpretation  of
he  categorization  of  these  staphylococci.  The  probabilistic
se  of  this  drug  has  undoubtedly  contributed  to  the  emer-
ence  of  this  resistance  [14],  which  has  now  led  us  to  exclude
eicoplanin  from  OAI  management  in  our  center.  The  emer-
ence  of  strains  resistant  to  linezolid  is  more  worrisome,  in
he  present  study  reaching  values  clearly  higher  than  those
eported  in  the  literature  (3.5%  in  2011)  [12,15,16].  The
roportion  of  Gram-negative  bacteria  remains  limited,  in
greement  with  the  data  in  the  literature  [8,9,17].  These
acterial  infections  are  most  often  hematogenous,  after  uri-
ary  tract  infections  when  associated  with  prostheses,  and
re  commonly  multimicrobial.  The  susceptibility  of  enter-
bacteria  to  third-generation  cephalosporins  is  preserved
nd  ESBL  bacteria  remain  anecdotic  for  the  moment  in
ur  center.  Nevertheless,  the  emergence  of  multiresistant
trains  to  beta-lactams,  including  carbapenems,  in  France
n  the  last  2  years  has  made  us  more  cautious.  P.  aeruginosa
ccounts  for  21%  of  Gram-negative  bacilli  isolated  versus  10%
or  Uc¸kay  et  al.  [18],  25%  for  Zmistowski  et  al.  [19],  and  40%
or  Hsieh  et  al.  [17].  Resistance  to  ceftazidime  involved  less
6t
r
a
o
o
u
s
p
l
i
a
C
A
d
b
m
b
i
i
t
e
D
T
c
R
[
[
[
[
[
[
[
[
[
[58  
han  18%  of  the  strains  in  2011  and  consequently  limits  the
isk  of  failure  of  these  drugs  frequently  used  in  probabilistic
ntibiotic  therapy  to  cover  Gram-negative  bacteria.
Finally,  P.  acnes  is  the  most  frequently  isolated  anaer-
bic  species,  with  a  signiﬁcant  increase  in  the  number
f  isolates  between  2002  and  2011.  This  phenomenon  is
ndoubtedly  inherent  to  the  prolonged  incubation  of  the
amples,  but  also  to  this  bacterium’s  recognized  pathogenic
ower,  which  forces  us  to  consider  it  as  one  of  the  estab-
ished  complications  in  shoulder  surgery  [10,20].  Despite  its
nsidious  clinical  expression,  P.  acnes  infections  present  few
ntibiotic  resistance  problems.
onclusion
ll  in  all,  over  the  last  10  years  this  epidemiological  study
oes  not  show  resistance  problems  for  the  Gram-negative
acilli.  On  the  other  hand,  the  CoNS,  which  account  for
ore  than  35%  of  the  bacteria  isolated  in  OAIs,  prove  to
e  the  major  problem  for  antibiotic  treatment.  The  growth
n  resistance  for  staphylococci  has  resulted  in  our  exclud-
ng  teicoplanin  and  linezolid  from  probabilistic  antibiotic
herapy.  The  results  of  this  study  encourage  monitoring  the
volution  of  our  local  ecology.
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